Open AccessTransitional Syndrome: From West to Lennox-'Gastaut Syndromes
Author(s) -
Julian Kenyon
Publication year - 2018
Publication title -
brain and neurological disorders
Language(s) - English
Resource type - Journals
ISSN - 2642-973X
DOI - 10.31579/2642-973x/001
Subject(s) - cannabidiol , nausea , medicine , cannabis , psychiatry
Background/Aim: Cannabinoids are widely used in the management of pain, nausea and cachexia in cancer patients. However, there has been no objective clinical evidence of any anticancer activity yet. The aim of this study was to assess the effects of Pharmaceutical-Grade Synthetic Cannabidiol on a range of Brain Tumours Patients and Methods: We analysed the data routinely collected as part of our treatment program in 11 Brain Cancer patients over a four- year period. Results: Clinical responses were seen in all of these 11 patients, including a reduction in tumour size, as shown by repeat scans. There were no side effects of any kind observed when using Pharmaceutical-Grade Synthetic Cannabidiol. Pharmaceutical-Grade Synthetic Cannabidiol was supplied by STI Pharmaceuticals. Conclusion: Pharmaceutical-Grade Synthetic Cannabidiol is a candidate for treating glioma patients.